{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-255127","form_type":"8-K","ticker":"IOBTQ","cik":"0001865494","company_name":"IO Biotech, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.165078+00:00","generated_at":"2026-05-30T02:15:51.219301+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"IO Biotech Q3 net loss $24.0M; Phase 3 melanoma trial on track for PFS in H1 2025","bullets":["Net loss $24.0M for Q3 2024 vs $21.7M in Q3 2023; R&D expenses $20.2M up from $17.7M.","Cash $80.2M as of Sep 30, 2024, down from $143.2M; cash runway into Q4 2025.","Phase 3 trial IO102-IO103 + pembrolizumab in advanced melanoma: PFS primary endpoint expected H1 2025.","Phase 2 SCCHN cohort met primary endpoint; data presented at ESMO and SITC.","Plans BLA submission in 2025 and potential US launch in 2026; IND for IO112 in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-255127","json":"https://secwatch.observer/filing/0001193125-24-255127.json","markdown":"https://secwatch.observer/filing/0001193125-24-255127.md","text":"https://secwatch.observer/filing/0001193125-24-255127.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1865494/000119312524255127/0001193125-24-255127-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1865494/000119312524255127/d793963d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:15:51.219301+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}